Summit Therapeutics Inc. (SMMT)
SMMT Stock Price Chart
Explore Summit Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze SMMT price movements and trends.
SMMT Company Profile
Discover essential business fundamentals and corporate details for Summit Therapeutics Inc. (SMMT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Mar 2015
Employees
159.00
Website
https://www.summittxinc.comCEO
Robert W. Duggan
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT Financial Timeline
Browse a chronological timeline of Summit Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is -$0.15.
Earnings released on 11 Aug 2025
EPS came in at -$0.76 falling short of the estimated -$0.09 by -736.91%.
Earnings released on 1 May 2025
EPS came in at -$0.09 surpassing the estimated -$0.09 by +3.25%.
Earnings released on 24 Feb 2025
EPS came in at -$0.08 surpassing the estimated -$0.08 by +2.21%.
Earnings released on 30 Oct 2024
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%.
Earnings released on 6 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 1 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 20 Feb 2024
EPS came in at -$0.04 , while revenue for the quarter reached -$297.04K .
Earnings released on 7 Nov 2023
EPS came in at -$0.03 .
Earnings released on 9 Aug 2023
EPS came in at -$0.02 , while revenue for the quarter reached $297.59K .
Earnings released on 11 May 2023
EPS came in at -$0.06 .
Earnings released on 9 Mar 2023
EPS came in at -$0.07 surpassing the estimated -$0.26 by +73.08%, while revenue for the quarter reached $866.49 .
Earnings released on 9 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.26 by +46.15%, while revenue for the quarter reached $243.40K .
Earnings released on 11 Aug 2022
EPS came in at -$0.17 surpassing the estimated -$0.27 by +37.04%, while revenue for the quarter reached $285.26K .
Earnings released on 11 May 2022
EPS came in at -$0.22 surpassing the estimated -$0.28 by +21.43%, while revenue for the quarter reached $327.89K .
Earnings released on 17 Mar 2022
EPS came in at -$0.28 falling short of the estimated -$0.27 by -3.70%, while revenue for the quarter reached $338.58K .
Earnings released on 15 Nov 2021
EPS came in at -$0.20 surpassing the estimated -$0.29 by +31.03%, while revenue for the quarter reached $1.77M , beating expectations by +3.64%.
Earnings released on 11 Aug 2021
EPS came in at -$0.27 falling short of the estimated -$0.18 by -50.00%, while revenue for the quarter reached $78.76K , beating expectations by +38.17%.
Earnings released on 17 May 2021
EPS came in at -$1.05 , while revenue for the quarter reached $265.26K .
Earnings released on 17 Mar 2021
EPS came in at -$0.90 , while revenue for the quarter reached $251.65K .
Earnings released on 16 Nov 2020
EPS came in at -$1.24 falling short of the estimated -$0.01 by -11.05K%, while revenue for the quarter reached $233.61K , missing expectations by -98.82%.
Earnings released on 29 Sept 2020
EPS came in at -$1.15 falling short of the estimated -$0.02 by -5.65K%, while revenue for the quarter reached $211.88K .
SMMT Stock Performance
Access detailed SMMT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.